Key Points
- CFO Aaron Freidin sold 45,806 shares on April 8 at an average of $49.92 for a total of $2,286,635.52, cutting his stake by 14.95% to 260,669 shares (worth about $13.01M).
- Freidin also made three sales in March totaling roughly $634,341 (12,720 shares), reflecting a recent pattern of insider selling.
- GRAIL has a $1.95 billion market cap, reported Q results with EPS of -$2.44 (beating estimates) and $43.6M revenue, and holds a consensus analyst rating of "Moderate Buy" with a $72.83 price target.
GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) CFO Aaron Freidin sold 45,806 shares of the company's stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the sale, the chief financial officer owned 260,669 shares in the company, valued at $13,012,596.48. This represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Aaron Freidin also recently made the following trade(s):
- On Monday, March 9th, Aaron Freidin sold 2,492 shares of GRAIL stock. The shares were sold at an average price of $47.89, for a total transaction of $119,341.88.
- On Thursday, March 5th, Aaron Freidin sold 655 shares of GRAIL stock. The stock was sold at an average price of $53.01, for a total value of $34,721.55.
- On Monday, March 2nd, Aaron Freidin sold 9,573 shares of GRAIL stock. The stock was sold at an average price of $50.17, for a total value of $480,277.41.
GRAIL Price Performance
Shares of GRAL stock opened at $47.56 on Friday. The company has a market cap of $1.95 billion, a PE ratio of -4.25 and a beta of 4.62. The stock's 50 day simple moving average is $64.95 and its two-hundred day simple moving average is $79.53. GRAIL, Inc. has a 1 year low of $21.80 and a 1 year high of $118.84.
GRAIL (NASDAQ:GRAL - Get Free Report) last released its earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, beating the consensus estimate of ($3.33) by $0.89. GRAIL had a negative return on equity of 17.11% and a negative net margin of 277.46%.The firm had revenue of $43.60 million for the quarter, compared to the consensus estimate of $43.33 million. Equities research analysts expect that GRAIL, Inc. will post -15.15 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of GRAIL in a report on Thursday, January 22nd. Morgan Stanley reduced their price objective on shares of GRAIL from $110.00 to $60.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 24th. Robert W. Baird set a $82.00 price objective on shares of GRAIL in a research note on Friday, February 20th. Guggenheim dropped their target price on GRAIL from $130.00 to $75.00 and set a "buy" rating for the company in a research report on Monday, March 30th. Finally, TD Cowen raised GRAIL from a "hold" rating to a "buy" rating and set a $65.00 target price on the stock in a research note on Wednesday, March 18th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $72.83.
Read Our Latest Research Report on GRAIL
Institutional Trading of GRAIL
Several institutional investors and hedge funds have recently made changes to their positions in GRAL. Royal Bank of Canada boosted its stake in shares of GRAIL by 17.7% during the first quarter. Royal Bank of Canada now owns 88,082 shares of the company's stock valued at $2,250,000 after purchasing an additional 13,264 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in GRAIL by 28.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company's stock valued at $76,000 after buying an additional 623 shares during the period. NewEdge Advisors LLC grew its stake in GRAIL by 390.3% in the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock worth $45,000 after acquiring an additional 1,401 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in GRAIL by 37.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company's stock worth $2,362,000 after acquiring an additional 25,177 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of GRAIL by 115.7% during the second quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company's stock worth $4,090,000 after acquiring an additional 42,675 shares during the period.
About GRAIL
(
Get Free Report)
GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.
Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
